How much is the market price of each box of Pitobrutinib/Pitobrutinib?

Pirtobrutinib is a new type of BTK inhibitor specifically designed to treat patients with relapsed or refractory hematological tumors. Its current main indications include: adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of therapy (including BTK inhibitors and BCL-2 inhibitors); and adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy (including BTK inhibitors and BCL-2 inhibitors). These patients usually have no standard treatment options and have poor prognosis. The launch of pitubrutinib provides them with a new treatment method.

In terms of market pricing, Pitobrutinib, as the original drug, is relatively expensive. It has been approved for marketing in China, but has not yet been covered by medical insurance. The specifications sold domestically are 100 mg × 14 tablets × 4 plates. Each box is priced at more than 40,000 yuan, which is a heavy burden for patients who take medicine for a long time. In overseas markets, the original drug Pitobrutinib has American and European versions. Common specifications include 50 mg × 30 tablets and 100 mg × 60 tablets. The price per box is close to 100,000 yuan. It is a high-priced anti-cancer drug in Europe and the United States and is mainly used for severe patients with few treatment options.

It is worth noting that generic drugs of pitobrutinib have appeared in some overseas regions. The ingredients of the drug are basically the same as the original drug, but the price has dropped significantly. For example, the version produced in Laos has a specification of 50 mg × 30 tablets and sells for more than 2,000 yuan per box, which is dozens of times lower than the original drug. Although generic drugs are more cost-effective, patients need to pay attention to channel formality and drug quality assurance when choosing. From a clinical perspective, the high price of pitubrutinib limits its popularity to a certain extent, but its status as a breakthrough BTK inhibitor is irreplaceable.

Reference materials:https://go.drugbank.com/drugs/DB17472